Radioactive 'Smart Bomb' targets advanced prostate cancer in first human trial
NCT ID NCT06052306
Summary
This early-stage study is testing a new radioactive drug called 225Ac-pelgi in men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug is designed to seek out and deliver radiation directly to cancer cells while sparing healthy tissue. Researchers will determine the safest and most effective dose while measuring how well it shrinks tumors and lowers PSA levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akademiska Sjukhuset - Fas-I-enheten
Uppsala, Uppsala County, 751 85, Sweden
-
CRST Oy - Clinical Research Services Turku
Turku, Southwest Finland, 20520, Finland
-
Cambridge University Hospitals NHS Foundation Trust | Addenbrookes Hospital - Clinical Research Centre
Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom
-
Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hopital Fleurimont
Sherbrooke, Quebec, J1H 5N4, Canada
-
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, H2X 3E4, Canada
-
City of Hope - Duarte Cancer Center
Duarte, California, 91010, United States
-
Docrates Mehiläinen Syöpäsairaala
Helsinki, Uusimaa, 00180, Finland
-
Erasmus Medisch Centrum
Rotterdam, South Holland, 3015 CE, Netherlands
-
HUS-Yhtymä, Helsingin yliopistollinen sairaala (HUS) - Syöpäkeskus
Helsinki, Uusimaa, 00029, Finland
-
IRCCS Istituto Nazionale Tumori Fondazione Pascale - S. C. Medicina Nucleare e Terapia Metabolica
Napoli, 80131, Italy
-
Istituto Europeo di Oncologia s.r.l - Medicina Nucleare
Milan, 20141, Italy
-
Kantonsspital Baden
Baden, Canton of Aargau, 5404, Switzerland
-
Karolinska Universitetssjukhuset - Fas I-enheten Solna CKC
Stockholm, Stockholm County, 171 76, Sweden
-
Kuopio University Hospital, Kuopion yliopistollinen sairaala (KYS) - Syövänhoitokeskus
Kuopio, Northern Savonia, 70210, Finland
-
M Health Fairview Masonic Cancer Clinic - Clinics and Surgery Center
Minneapolis, Minnesota, 55455, United States
-
McGill University Health Centre (MUHC) - Research Institute (RI) - McConnell Centre for Innovative Medicine (CIM)
Montreal, Quebec, H4A 3J1, Canada
-
Sahlgrenska Universitetssjukhuset - Klinisk prövningsenhet Fas I/FIH
Gothenburg, Västra Götaland County, 413 46, Sweden
-
Skånes Universitetssjukhus Lund - Onkologens kliniska forskningsenhet
Lund, Skåne County, 221 85, Sweden
-
Tampere University Hospital, Tampereen yliopistollinen sairaala (TAYS) - Syöpäkeskus
Tampere, Pirkanmaa, 33520, Finland
-
The Newcastle upon Tyne Hospitals NHS Foundation Trust | Freeman Hospital - Cancer Trials Research Centre
Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom
-
The Royal Marsden NHS Foundation Trust | Sutton - Oak Foundation Drug Development Unit
Sutton, Surrey, SM2 5PT, United Kingdom
-
The University of Texas MD Anderson Cancer Center - Texas Medical Center
Houston, Texas, 77030, United States
-
Universitair Medisch Centrum Groningen
Groningen, 9713 GZ, Netherlands
-
University College London Hospitals NHS Foundation Trust | University College Hospital - NIHR UCLH Clinical Research Facility
London, Greater London, W1T 7HA, United Kingdom
-
Universitätsspital Basel
Basel, Canton of Basel-City, 4056, Switzerland
-
Univestitätsspital Zürich (USZ)
Zurich, 8091, Switzerland
-
Utah Cancer Specialists Cancer Center - Medical Oncology
Salt Lake City, Utah, 84106, United States
-
XCancer Omaha
Omaha, Nebraska, 68130, United States
Conditions
Explore the condition pages connected to this study.